Quest Diagnostics (DGX) Reaches $98.16 After 7.00% Down Move; Eminence Capital LP Has Cut By $816,420 Its Ptc (PTC) Position

April 22, 2018 - By Adrian Erickson

Quest Diagnostics Incorporated (NYSE:DGX) Logo

The stock of Quest Diagnostics Incorporated (NYSE:DGX) is a huge mover today! The stock decreased 3.28% or $3.33 during the last trading session, reaching $98.16. About 1.78M shares traded or 63.87% up from the average. Quest Diagnostics Incorporated (NYSE:DGX) has risen 1.33% since April 22, 2017 and is uptrending. It has underperformed by 10.22% the S&P500.The move comes after 8 months negative chart setup for the $13.33B company. It was reported on Apr, 22 by Barchart.com. We have $91.29 PT which if reached, will make NYSE:DGX worth $933.03 million less.

Eminence Capital Lp decreased Ptc Inc (PTC) stake by 0.69% reported in 2017Q4 SEC filing. Eminence Capital Lp sold 13,607 shares as Ptc Inc (PTC)’s stock rose 31.32%. The Eminence Capital Lp holds 1.96M shares with $119.03 million value, down from 1.97 million last quarter. Ptc Inc now has $9.77B valuation. The stock decreased 1.02% or $0.87 during the last trading session, reaching $84.05. About 1.07M shares traded or 14.32% up from the average. PTC Inc. (NASDAQ:PTC) has risen 49.73% since April 22, 2017 and is uptrending. It has outperformed by 38.18% the S&P500.

Since January 2, 2018, it had 0 buys, and 13 sales for $30.90 million activity. Another trade for 106,840 shares valued at $11.43 million was made by RUSCKOWSKI STEPHEN H on Monday, January 29. $6.30M worth of Quest Diagnostics Incorporated (NYSE:DGX) shares were sold by Davis J. E.. $561,156 worth of Quest Diagnostics Incorporated (NYSE:DGX) was sold by Doherty Catherine T.. PREVOZNIK MICHAEL E sold 4,128 shares worth $416,928. $8.72M worth of stock was sold by Cohen Jon R on Thursday, March 8. The insider Klug Robert A sold 1,157 shares worth $119,932.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company has market cap of $13.33 billion. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, gene and esoteric testing, and drugs-of-abuse testing, as well as anatomic pathology services, and related services and insights. It has a 17.85 P/E ratio. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum, and Care360 brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, and phlebotomists in physician offices.

Investors sentiment decreased to 0.92 in 2017 Q4. Its down 0.06, from 0.98 in 2017Q3. It worsened, as 52 investors sold Quest Diagnostics Incorporated shares while 192 reduced holdings. 67 funds opened positions while 158 raised stakes. 115.48 million shares or 1.22% less from 116.90 million shares in 2017Q3 were reported. Regions Finance reported 1,371 shares. Victory Mngmt Inc, Ohio-based fund reported 2.49 million shares. Sg Americas Secs Limited Com holds 61,032 shares or 0.06% of its portfolio. State Teachers Retirement Systems owns 228,910 shares. Wellington Management Gru Ltd Liability Partnership reported 241,226 shares. Cipher Cap Limited Partnership has 0.61% invested in Quest Diagnostics Incorporated (NYSE:DGX) for 77,916 shares. Livforsakringsbolaget Skandia Omsesidigt reported 59,835 shares. Thrivent Finance For Lutherans stated it has 5,535 shares. 17,905 were reported by Laffer Investments. Fny Managed Accounts Limited Liability Com accumulated 68 shares or 0.01% of the stock. Putnam Investments Ltd Liability Corp invested 0% in Quest Diagnostics Incorporated (NYSE:DGX). 19,789 were reported by Bokf Na. The Ontario – Canada-based Royal Bankshares Of Canada has invested 0.01% in Quest Diagnostics Incorporated (NYSE:DGX). Zwj Invest Counsel stated it has 2,819 shares or 0.02% of all its holdings. Amp Investors Ltd has 0.06% invested in Quest Diagnostics Incorporated (NYSE:DGX).

Among 21 analysts covering Quest Diagnostics (NYSE:DGX), 9 have Buy rating, 1 Sell and 11 Hold. Therefore 43% are positive. Quest Diagnostics had 69 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Thursday, October 5 by Robert W. Baird. Credit Suisse maintained Quest Diagnostics Incorporated (NYSE:DGX) rating on Thursday, September 28. Credit Suisse has “Hold” rating and $99.0 target. On Friday, October 21 the stock rating was maintained by Mizuho with “Neutral”. Robert W. Baird maintained it with “Hold” rating and $105.0 target in Sunday, September 17 report. As per Tuesday, July 25, the company rating was upgraded by Bank of America. The firm earned “Buy” rating on Wednesday, April 26 by Mizuho. Mizuho maintained Quest Diagnostics Incorporated (NYSE:DGX) on Thursday, October 22 with “Neutral” rating. Canaccord Genuity maintained Quest Diagnostics Incorporated (NYSE:DGX) on Friday, November 13 with “Buy” rating. Mizuho maintained the shares of DGX in report on Thursday, October 19 with “Buy” rating. The stock has “Market Perform” rating by Raymond James on Monday, September 25.

Eminence Capital Lp increased Altaba Inc stake by 398,715 shares to 755,536 valued at $52.77M in 2017Q4. It also upped Wendys Co (NASDAQ:WEN) stake by 2.78 million shares and now owns 11.68M shares. Cornerstone Ondemand Inc (NASDAQ:CSOD) was raised too.

Among 17 analysts covering PTC (NASDAQ:PTC), 12 have Buy rating, 0 Sell and 5 Hold. Therefore 71% are positive. PTC had 55 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Buy” rating by Wedbush given on Monday, September 21. Barclays Capital maintained the stock with “Overweight” rating in Thursday, April 19 report. On Thursday, January 18 the stock rating was maintained by Barclays Capital with “Buy”. The stock of PTC Inc. (NASDAQ:PTC) has “Buy” rating given on Wednesday, January 17 by KeyBanc Capital Markets. As per Thursday, January 25, the company rating was maintained by Robert W. Baird. Bank of America upgraded the shares of PTC in report on Thursday, January 18 to “Neutral” rating. KeyBanc Capital Markets initiated it with “Overweight” rating and $40 target in Thursday, October 8 report. The rating was maintained by Wedbush with “Outperform” on Thursday, January 19. Evercore maintained PTC Inc. (NASDAQ:PTC) rating on Monday, June 12. Evercore has “Buy” rating and $6500 target. On Thursday, July 30 the stock rating was maintained by Barclays Capital with “Overweight”.

Quest Diagnostics Incorporated (NYSE:DGX) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>